Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis from Two Phase III Studies for Anamorelin in Cachectic Patients with Non-Small Cell Lung Cancer (NSCLC)
Lugano, Switzerland, June 1, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it will present…